[10, 11] Sodium-glucose cotransporter 2 inhibitor (SGLT2i) is a new class of anti-diabetic drug which inhibit sodium and glucose reabsorption in proximal tubules of the kidney and thereby lower blood glucose in patients with type 2 diabetes mellitus (T2DM) [12]. This evidence concerns the gene SLC5A2 and diabetes mellitus.